Patents Assigned to Xencor, Inc.
  • OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20070224192
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: May 11, 2007
    Publication date: September 27, 2007
    Applicant: Xencor, Inc.
    Inventors: Gregory Lazar, Arthur Chirino, Wei Dang, John Desjarlais, Stephen Doberstein, Robert Hayes, Sher Karki, Omid Vafa
  • CD20 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20070224189
    Abstract: The present invention relates to CD20 optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: December 29, 2006
    Publication date: September 27, 2007
    Applicant: Xencor, Inc.
    Inventors: Gregory Lazar, Arthur Chirino, Wei Dang, John Desjarlais, Stephen Doberstein, Robert Hayes, Sher Karki, Omid Vafa
  • CD52 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20070219133
    Abstract: The present invention relates to CD52 optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: December 29, 2006
    Publication date: September 20, 2007
    Applicant: Xencor, Inc.
    Inventors: Gregory Lazar, Arthur Chirino, Wei Dang, John Desjarlais, Stephen Doberstein, Robert Hayes, Sher Karki, Omid Vafa
  • Her2/neu OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20070202098
    Abstract: The present invention relates to Her2/neu optimized Sc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: December 29, 2006
    Publication date: August 30, 2007
    Applicant: Xencor, Inc.
    Inventors: Gregory Lazar, Arthur Chirino, Wei Dang, John Desjarlais, Stephen Doberstein, Robert Hayes, Sher Karki, Omid Vafa
  • TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
    Publication number: 20070172449
    Abstract: Combination therapies comprising novel TNF-? proteins for the treatment of TNF-? related disorders are provided herein.
    Type: Application
    Filed: November 13, 2006
    Publication date: July 26, 2007
    Applicant: Xencor, Inc.
    Inventors: David Carmichael, John Desjarlais, David Szymkowski, Jonathan Zalevsky
  • OPTIMIZED ANTI-CD30 ANTIBODIES
    Publication number: 20070166309
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Application
    Filed: March 15, 2007
    Publication date: July 19, 2007
    Applicant: Xencor, Inc.
    Inventors: Gregory Lazar, John Desjarlais, Philip Hammond, David Carmichael, Bao-lu Chen, Seung Chu, Sher Karki
  • Optimized anti-CD30 antibodies
    Publication number: 20070148171
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Application
    Filed: October 6, 2006
    Publication date: June 28, 2007
    Applicant: XENCOR, INC.
    Inventors: Gregory Lazar, John Desjarlais, Philip Hammond, David Carmichael, Bao-lu Chen, Seung Chu, Sher Karki
  • Nucleic acids and protein variants of hG-CSF with granulopoietic activity
    Patent number: 7208473
    Abstract: The invention relates to novel granulopoietic activity (GPA) proteins and nucleic acids. The invention further relates to the use of the GPA proteins in the treatment of G-CSF related disorders.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: April 24, 2007
    Assignee: Xencor, Inc.
    Inventors: Bassil I. Dahiyat, Peizhi Luo
  • Polypeptides including modified constant regions
    Publication number: 20070041966
    Abstract: Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having increased binding affinity for an Fc?R, which processes comprise modifying the polypeptides by substitution of the amino acid at position 268 of a human IgG CH2 region for a non-native polar or charged amino acid e.g. Gin, Asn, Glu, or Asp. also provided are corresponding polypeptides, nucleic acids, and methods of use of the same e.g. in improved lytic therapies.
    Type: Application
    Filed: October 27, 2006
    Publication date: February 22, 2007
    Applicant: XENCOR, INC.
    Inventors: Kathryn Armour, Michael Clark
  • BMP-2 variants with improved properties
    Publication number: 20060235204
    Abstract: The invention relates to variants of BMP-2 with improved properties and methods for their use.
    Type: Application
    Filed: June 20, 2006
    Publication date: October 19, 2006
    Applicant: Xencor, Inc.
    Inventors: John Desjarlais, Shannon Marshall, Jonathan Zalevsky
  • Nucleic acids and proteins with thioredoxin reductase activity
    Patent number: 7071307
    Abstract: The present invention relates to the use of a variety of methods for generating functional thioredoxin reductase variants in which at least one physical, chemical or biological property of the variant is altered in a specific and desired manner when compared to the wild-type protein.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: July 4, 2006
    Assignees: Syngenta Participations AG, Xencor, Inc.
    Inventors: Bipin K. Dalmia, Steven P. Briggs, Greg del Val, John R. Desjarlais, Peter Heifetz, Peter Luginbuhl, Umesh Muchhal
  • Analysis of MHC-peptide binding interactions
    Publication number: 20060084116
    Abstract: Methods, apparatuses, and compounds for screening or detecting binding of candidate peptides to an MHC construct is provided. A first component including at least one candidate peptides and a second component including at least one MHC construct are contacted. One of the components is immobilized on a solid support. The presence, absence, or quantity of binding of the peptide and said MHC construct is then determined.
    Type: Application
    Filed: September 13, 2005
    Publication date: April 20, 2006
    Applicant: Xencor, Inc.
    Inventor: Umesh Muchhal
  • Monomeric immunoglobulin Fc domains
    Publication number: 20060074225
    Abstract: Design and production of immunoglobulin Fc domains including variants to stabilize their monomeric forms are provided.
    Type: Application
    Filed: September 14, 2005
    Publication date: April 6, 2006
    Applicant: Xencor, Inc.
    Inventors: Aaron Chamberlain, John Desjarlais
  • Erythropoietin derivatives with altered immunogenicity
    Publication number: 20060073563
    Abstract: The present invention relates to novel erythropoietin protein variants with altered immunogenicity.
    Type: Application
    Filed: September 2, 2005
    Publication date: April 6, 2006
    Applicant: Xencor, Inc.
    Inventor: Shannon Marshall
  • Apolipoprotein A-I derivatives with altered immunogenicity
    Publication number: 20060030525
    Abstract: The present invention relates to novel apolipoprotein A-I proteins with altered immunogenicity.
    Type: Application
    Filed: July 25, 2005
    Publication date: February 9, 2006
    Applicant: Xencor, Inc.
    Inventors: Shannon Marshall, Gregory Moore
  • Optimized Fc variants
    Publication number: 20060024298
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: May 5, 2005
    Publication date: February 2, 2006
    Applicant: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes
  • Methods of generating variant proteins with increased host string content and compositions thereof
    Publication number: 20060008883
    Abstract: The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods.
    Type: Application
    Filed: December 3, 2004
    Publication date: January 12, 2006
    Applicant: Xencor, Inc.
    Inventors: Gregory Lazar, John Desjarlais, Philip Hammond
  • Protein engineering with analogous contact environments
    Publication number: 20060003412
    Abstract: The invention relates to novel methods for engineering protein sequences using structural and homology information.
    Type: Application
    Filed: June 9, 2005
    Publication date: January 5, 2006
    Applicant: Xencor, Inc.
    Inventors: Aaron Chamberlain, John Desjarlais
  • Immunoglobulin variants outside the Fc region
    Publication number: 20050244403
    Abstract: The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application.
    Type: Application
    Filed: March 24, 2005
    Publication date: November 3, 2005
    Applicant: Xencor, Inc.
    Inventors: Gregory Lazar, Sher Karki
  • Nucleic acids and proteins with growth hormone activity
    Patent number: 6946265
    Abstract: The invention relates to novel growth hormone activity (GHA) proteins and nucleic acids. The invention further relates to the use of the GHA proteins in the treatment of growth hormone related disorders.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: September 20, 2005
    Assignee: Xencor, Inc.
    Inventors: Anton Filikov, Bassil I. Dahiyat